Recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib was approved by FDA to treat patients harboring BRAF (V600E) mutation in NSCLC (non-small cell lung cancer) or melanoma. Here, MAP2K7 is linked to non-small cell lung carcinoma.